These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 10022154)

  • 1. Rational management of posttransplant lymphoproliferative disorder in pediatric recipients.
    Praghakaran K; Wise B; Chen A; Schwarz K; Colombani P
    J Pediatr Surg; 1999 Jan; 34(1):112-5; discussion 115-6. PubMed ID: 10022154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
    McDiarmid SV; Jordan S; Kim GS; Toyoda M; Goss JA; Vargas JH; Martín MG; Bahar R; Maxfield AL; Ament ME; Busuttil RW
    Transplantation; 1998 Dec; 66(12):1604-11. PubMed ID: 9884246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy.
    Cacciarelli TV; Green M; Jaffe R; Mazariegos GV; Jain A; Fung JJ; Reyes J
    Transplantation; 1998 Oct; 66(8):1047-52. PubMed ID: 9808490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.
    Newell KA; Alonso EM; Whitington PF; Bruce DS; Millis JM; Piper JB; Woodle ES; Kelly SM; Koeppen H; Hart J; Rubin CM; Thistlethwaite JR
    Transplantation; 1996 Aug; 62(3):370-5. PubMed ID: 8779685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
    Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression.
    Shapiro R; Nalesnik M; McCauley J; Fedorek S; Jordan ML; Scantlebury VP; Jain A; Vivas C; Ellis D; Lombardozzi-Lane S; Randhawa P; Johnston J; Hakala TR; Simmons RL; Fung JJ; Starzl TE
    Transplantation; 1999 Dec; 68(12):1851-4. PubMed ID: 10628763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression.
    Ellis D; Jaffe R; Green M; Janosky JJ; Lombardozzi-Lane S; Shapiro R; Scantlebury V; Vivas C; Jordan ML
    Transplantation; 1999 Oct; 68(7):997-1003. PubMed ID: 10532541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttransplant lymphoproliferative disorder in pediatric renal transplantation.
    Srivastava T; Zwick DL; Rothberg PG; Warady BA
    Pediatr Nephrol; 1999 Nov; 13(9):748-54. PubMed ID: 10603113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
    Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
    Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epstein-Barr virus infections in children after transplantation of the small intestine.
    Finn L; Reyes J; Bueno J; Yunis E
    Am J Surg Pathol; 1998 Mar; 22(3):299-309. PubMed ID: 9500771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple clinical presentations of lymphoproliferative disorders in pediatric liver transplant recipients: a single-center experience.
    Pinho-Apezzato ML; Tannuri U; Tannuri AC; Mello ES; Lima F; Gibelli NE; Santos MM; Ayoub AA; Maksoud-Filho JG; Velhote MC; Silva MM; Andrade WC; Miyatani HT
    Transplant Proc; 2010 Jun; 42(5):1763-8. PubMed ID: 20620519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients.
    Serinet MO; Jacquemin E; Habes D; Debray D; Fabre M; Bernard O
    J Pediatr Gastroenterol Nutr; 2002 Apr; 34(4):389-93. PubMed ID: 11930095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-transplant lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome from a single-centre experience with >1000 liver transplantations.
    Mumtaz K; Faisal N; Marquez M; Healey A; Lilly LB; Renner EL
    Can J Gastroenterol Hepatol; 2015; 29(8):417-22. PubMed ID: 26076399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.
    Kogan-Liberman D; Burroughs M; Emre S; Moscona A; Shneider BL
    J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):445-9. PubMed ID: 11698761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early posttransplant lymphoproliferative disease in pediatric liver transplant recipients.
    Roque J; Rios G; Humeres R; Volpi C; Herrera JM; Schultz M; Rios H; Rius M; Salgado C; Hepp J
    Transplant Proc; 2006 Apr; 38(3):930-1. PubMed ID: 16647513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
    Lam JKP; Azzi T; Hui KF; Wong AMG; McHugh D; Caduff N; Chan KH; Münz C; Chiang AKS
    Front Immunol; 2020; 11():1231. PubMed ID: 32625211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.
    Ganschow R; Schulz T; Meyer T; Broering DC; Burdelski M
    J Pediatr Gastroenterol Nutr; 2004 Feb; 38(2):198-203. PubMed ID: 14734884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.
    Narkewicz MR; Green M; Dunn S; Millis M; McDiarmid S; Mazariegos G; Anand R; Yin W;
    Liver Transpl; 2013 Jul; 19(7):730-40. PubMed ID: 23696264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posttransplant lymphoproliferative disorder in liver allograft biopsies: a comparison of three methods for the demonstration of Epstein-Barr virus.
    Lones MA; Shintaku IP; Weiss LM; Thung SN; Nichols WS; Geller SA
    Hum Pathol; 1997 May; 28(5):533-9. PubMed ID: 9158700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.